CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study The Evolution of β-Blockers in Coronary Artery Disease and Heart Failure (Part 1/5) The conductive function of biopolymer corrects myocardial scar conduction blockage and resynchronizes contraction to prevent heart failure Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine - The ROPA-DOP Trial 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Clinical Data Standards for Heart Failure) Proteomics to Improve Phenotyping in Obese Patients with Heart Failure with Preserved Ejection Fraction

Clinical Trial2018 Jun 12;71(23):2628-2639.

JOURNAL:J Am Coll Cardiol. Article Link

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Kosiborod M, Lam CSP, CVD-REAL Investigators and Study Group. Keywords: SGLT-2 inhibitor; death; diabetes mellitus; heart failure; observational studies; sodium glucose cotransporter-2 inhibitors

FULL TEXT PDF